Skip to content
跳至主要內容
SPY
···
QQQ
···
IWM
···
DIA
···
AAPL
···
MSFT
···
NVDA
···
GOOGL
···
AMZN
···
META
···
TSLA
···
BRK.B
···
JPM
···
GLD
···
TLT
···
BTC
···
ETH
···
VIXY
···
UUP
···
USO
···
SPY
···
QQQ
···
IWM
···
DIA
···
AAPL
···
MSFT
···
NVDA
···
GOOGL
···
AMZN
···
META
···
TSLA
···
BRK.B
···
JPM
···
GLD
···
TLT
···
BTC
···
ETH
···
VIXY
···
UUP
···
USO
···
Stock detail
Loading institutional stock data...
← BACK TO COCKPIT
ALL TICKERS →
OPTIONS CHAIN →
CRVS
Corvus Pharmaceuticals, Inc.
NASDAQGM
Biotechnology
United States
$14.46
▼
-0.19 (-1.30%)
OPEN
—
OPEN
$14.34
HIGH
$14.74
LOW
$14.34
PREV CLOSE
$14.65
VOLUME
239.2K
0.23x avg
BID / ASK
10.15 / 18.20
spr 8.05
MARKET CAP
$1.22B
DAY RANGE
$14.34
$14.74
P/E (TTM)
—
Fwd -13.5
EPS (TTM)
-0.64
DIV YIELD
—
52W HIGH
$26.95
-46.3%
52W LOW
$5.64
+156.4%
BETA
0.87
vs S&P 500
DES
FA
GP
OPT
HLDR
EARN
CMP
COMPARE
ASK DESK
PRE-MARKET
$14.34
-0.31
(-2.12%)
LAST SURPRISE
—
—
NEXT EARNINGS
—
—
CATALYST
No fresh catalyst
—
ANALYST
—
—
SHORT INT
—
—
OPTIONS IV
—
—
CRVS
$14.46
▼
-1.30%
Chart
Valuation
Financials
Peers
News
CRVS · K 線技術分析（即時、可互動）
basic
pro
快速分析（約 90–120 秒）
Loading K-line chart…
按上方「快速分析」，研究台會以這張 K 線為起點跑一輪快速回答：三個分析師視角（總經、基本面、技術面）加交易計畫與風險統計，約 90–120 秒。想要五隊深度研究與機構級報告，請在研究台把模式切到「深度」。
1-YEAR PRICE
One-Year Trajectory
RISK-ON
253 BARS · +152.4% YOY
1-year price chart. Started at 5.73, currently 14.46, up 152.4 percent. Range 5.73 to 25.52 over 253 data points.
2025-09-04
$5.73 → $14.46 (+152.4%)
2026-09-04
§ Valuation
Loading § Valuation
§ Multi-Year Financials
Loading § Multi-Year Financials
§ Peers
Loading § Peers
§ Recent News
Loading § Recent News
EDITORIAL · NOT INVESTMENT ADVICE.
Data sources: Finnhub (quote / profile / news / peers) + Yahoo (stats) + SEC EDGAR XBRL (financials + DCF). All values cached for 5 minutes via ISR.
VALUATION
Deterministic Valuation (SEC EDGAR + Finnhub)
—
NO DCF
DCF Fair Value
—
DCF vs Spot
—
Comps Fair Value
$11.96
WACC Used
+7.0%
Terminal g
+3.5%
Verdict: strong-sell
· peers $11.96 (-17.3%)
Peers:
MGTX PE16
MNKD
JBIO
JANX
GLUE
KURA
SANA
1228.HK
⚠ DCF skipped: missing FCF or shares data from SEC EDGAR. Often the case for non-US issuers.
FINANCIALS
Multi-Year Financials (SEC XBRL)
—
3 FY · NO YOY
FY
Revenue
Net Income
OCF
FCF
Assets
2025-12
—
-$15.3M
-$32.8M
-$33.0M
$71.1M
2024-12
—
-$62.3M
-$25.4M
—
$68.9M
2023-12
—
-$27.0M
-$23.9M
-$24.0M
$45.6M
PEERS
Sector & Industry Peers
CALM
10 PEERS · FINNHUB
MGTX
MNKD
JBIO
JANX
GLUE
KURA
SANA
1228.HK
VOR
SLDB
NEWS
Recent News (past 14 days)
CALM
10 HEADLINES · LAST 14 DAYS
Corvus Pharmaceuticals to Present at the 2026 Cantor Global Healthcare Conference
GlobeNewswire · 2026-09-03
Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial
GlobeNewswire · 2026-08-27
Corvus Pharmaceuticals (CRVS): This Clinical-Stage Drugmaker Just Got A Lot More Interesting
Insider Monkey · 2026-08-17
Corvus Pharmaceuticals (CRVS) Q2 2026 Earnings Call Transcript
Motley Fool · 2026-08-14
Corvus Pharmaceuticals Inc (CRVS) (Q2 2026) Earnings Call Highlights: Advancing Soquelitinib ...
GuruFocus.com · 2026-08-07
Corvus Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
Moby · 2026-08-07
Corvus Pharmaceuticals Q2 Earnings Call Highlights
MarketBeat · 2026-08-07
Corvus: Q2 Earnings Snapshot
Associated Press · 2026-08-06